Largest positions
| Issuer | Class | Value | Share |
|---|---|---|---|
| Veradermics, Inc..Common Stock | Common Stock | $295M | 28.4% |
| Zenas Biopharma, Inc.Common Stock | Common Stock | $128M | 12.3% |
| Crispr Therapeutics AGCommon Shares | Common Shares | $111M | 10.7% |
| Avalyn Pharma, Inc.Common Stock | Common Stock | $109M | 10.5% |
| Design Therapeutics, Inc..Common Stock | Common Stock | $94.4M | 9.1% |
| Odyssey Therapeutics, Inc..Common Stock | Common Stock | $71M | 6.8% |
| Alumis Inc..Common Stock | Common Stock | $55.2M | 5.3% |
| Oric Pharmaceuticals, Inc..Common Stock | Common Stock | $50M | 4.8% |
| Mineralys Therapeutics Inc..Common Stock | Common Stock | $42.2M | 4.1% |
| Ars Pharmaceuticals, Inc..Common Stock | Common Stock | $32.1M | 3.1% |
| Mobia Medical, Inc.Common Stock | Common Stock | $26.6M | 2.6% |
| Nkarta, Inc..Common Stock | Common Stock | $9.43M | 0.9% |
| Oculis Holding AGOrdinary Shares | Ordinary Shares | $8.89M | 0.9% |
| Ultragenyx Pharmaceutical Inc..Common Stock | Common Stock | $4.6M | 0.4% |
| Engene Holdings Inc..Common Shares | Common Shares | $1.29M | 0.1% |
- Class
- Common Stock
- Share
- 28.4%
- Class
- Common Stock
- Share
- 12.3%
- Class
- Common Shares
- Share
- 10.7%
- Class
- Common Stock
- Share
- 10.5%
- Class
- Common Stock
- Share
- 9.1%
- Class
- Common Stock
- Share
- 6.8%
- Class
- Common Stock
- Share
- 5.3%
- Class
- Common Stock
- Share
- 4.8%
- Class
- Common Stock
- Share
- 4.1%
- Class
- Common Stock
- Share
- 3.1%
- Class
- Common Stock
- Share
- 2.6%
- Class
- Common Stock
- Share
- 0.9%
- Class
- Ordinary Shares
- Share
- 0.9%
- Class
- Common Stock
- Share
- 0.4%
- Class
- Common Shares
- Share
- 0.1%
The share class is shown on a wider screen.
The 15 largest of 15 positions by value, with holdings of the same security combined. Share counts and quarter-on-quarter changes for each position are on EDGAR. View the full information table on EDGAR
This filing
- Form
- 13F-HR
- CIK
- 1910264
- File number
- 028-21964
- Options
- 0 call, 0 put
- In the 25 largest
- 100.0%
- Prior quarter
- $915M at 31 March 2026
- Positions opened
- 3
- Positions closed
- 2
Common questions
What are SR One Capital Management’s 13F holdings worth?
$1.04 billion across 15 positions for the quarter ended 30 June 2026.
What is SR One Capital Management’s largest 13F holding?
Veradermics, Inc. (Common Stock) was the largest position at $295 million, or 28.4% of reported 13F value, as of 30 June 2026.
How concentrated is SR One Capital Management’s 13F portfolio?
The ten largest positions accounted for 95.1% of reported value and the twenty-five largest for 100.0%, across 15 positions as of 30 June 2026.
Does Form 13F show everything SR One Capital Management manages?
No. Form 13F covers only long positions in exchange-traded securities over which the manager has investment discretion, valued at quarter end. It excludes cash, most bonds, private funds, and any assets the firm does not have discretion over, so it is neither the firm's total assets nor any individual client's portfolio.
How often does SR One Capital Management file its 13F?
Every quarter. Managers file within 45 days of each quarter's end, so the figures are a snapshot that changes between filings. This page shows the quarter ended 30 June 2026.
Answered from this filing and the prior quarter's.